Independent vs. Chain Pharmacy Valuation: 2026 Guide

Script Count Benchmarks: Where Do Independents and Chains Actually Land

Script count is the foundational metric for pharmacy valuation. But the benchmarks for independents and chain locations look very different.

**Independent pharmacies:** The typical independent in a suburban or urban market fills 150–400 scripts per day. Below 100 scripts/day the economics are borderline — dispensing fees barely cover overhead. Above 400 scripts/day, the independent is operating at chain-like volume but often with leaner staffing.

**Chain pharmacy locations:** High-volume chain locations (Walgreens, CVS, Rite Aid) fill 400–800 scripts per day. They achieve this volume through PBM preferred network positioning, mail order co-dispensing programs, and aggressive patient acquisition. Chain economics at high volume look different than independent economics — lower dispensing margin per script, offset by volume.

**The valuation implication:** Chains pay for volume. A 250-script-per-day independent selling to a chain buyer will command a lower multiple than the same volume location in a preferred PBM network. Independents selling to other independents trade at margin-based multiples, rewarding profitability over raw volume.

**Benchmark multiples by script count:** - 100–150 scripts/day independent: 3x–3.5x EBITDA - 150–250 scripts/day independent: 3.5x–4.5x EBITDA - 250–400 scripts/day independent: 4x–5x EBITDA - 400+ scripts/day (any type): 4.5x–6x EBITDA depending on buyer type

DIR Fee Impact on Independent Pharmacy EBITDA Margins

DIR fees compressed independent pharmacy EBITDA margins by 2–5 percentage points throughout 2019–2023. Understanding how the post-2024 CMS reforms changed this is critical for buyers evaluating pharmacies with historical financials.

**Pre-2024 reality:** A pharmacy reporting 12% EBITDA margins on its P&L might actually be delivering 9% margins on a cash-received basis after DIR clawbacks. The P&L recognized dispensing fees at point-of-sale; the DIR recoupment showed up 6–18 months later as a deduction. Buyers analyzing 2021–2023 financials should ask specifically for DIR reconciliation schedules.

**Post-2024 CMS reform impact:** CMS required PBMs to reflect DIR-equivalent adjustments at the point of sale beginning January 2024. The immediate effect: lower point-of-sale dispensing fees but no retroactive clawbacks. For most pharmacies with significant Medicare Part D volume, this trade-off was roughly revenue-neutral but significantly improved cash flow predictability.

**How this affects your analysis of 2024–2026 financials:** A pharmacy showing strong EBITDA margins on 2024–2025 financials should actually be performing better on an apples-to-apples basis than the same pharmacy in 2022. If margins look worse post-2024, that's a signal — it could mean the pharmacy's PBM rate negotiations went poorly in the new environment.

**Chain pharmacy DIR exposure:** Chain pharmacies have significantly more negotiating leverage with PBMs and were less exposed to DIR fee compression in the pre-2024 period. This is one reason chain pharmacy EBITDA margins, while lower per-script, were more predictable.

340B Program Revenue: How It Differentiates Independent Pharmacies

The 340B drug pricing program is almost exclusively relevant to independent pharmacies acting as contract pharmacies for FQHCs, Ryan White clinics, and other covered entities. Chain pharmacies rarely participate as contract pharmacies.

**How 340B creates value for independents:** A covered entity (federally qualified health center, for example) purchases drugs at 340B discounted prices — sometimes 25–50% below wholesale acquisition cost. The covered entity then designates a contract pharmacy (your independent) to dispense those drugs to their patients. The contract pharmacy dispenses at standard reimbursement rates. The spread between acquisition cost and reimbursement is split between the covered entity and the contract pharmacy.

**Revenue magnitude:** A pharmacy with one active FQHC 340B agreement might generate $80K–$200K/year in incremental net revenue depending on prescription volume and drug mix. A pharmacy with three 340B agreements in a high-density urban market might generate $300K–$500K/year.

**Stability risk:** As noted in the pharmacy acquisition multiples guide, drug manufacturers have been restricting 340B contract pharmacy pricing. Some manufacturers now limit 340B pricing to a single contract pharmacy per covered entity location, significantly reducing the volume available to any individual contract pharmacy. Model 340B revenue conservatively — assume 20–30% reduction stress case.

**Valuation treatment:** 340B revenue should be capitalized at 2x–3x EBITDA, not the 4x–5x multiple applied to core dispensing revenue. The regulatory and manufacturer restriction risk justifies the discount.

Front-End vs. Dispensing Revenue: The Mix Matters

Independent pharmacies often generate 10–25% of total revenue from front-end (non-prescription) sales — OTC medications, health and beauty products, gifts, and specialty items. Chain pharmacies generate a much higher proportion from front-end (sometimes 30–40% of gross revenue).

**Why front-end revenue matters for valuation:** Front-end revenue is generally lower margin than dispensing revenue (15–30% gross margin vs. 20–40% for generic dispensing), but it's also not subject to PBM DIR fee risk. A pharmacy with a healthy front-end diversifies its PBM exposure.

**The specialty pharmacy premium:** Specialty medications (oncology, immunology, HIV, rare disease) represent the highest-margin dispensing category. Specialty prescriptions require more clinical support, patient counseling, and often temperature-controlled storage — but the dispensing fees are 3–10x higher than commodity generics.

An independent pharmacy with 15% specialty volume and a dedicated specialty consultation area commands a significant premium over a generics-heavy pharmacy with the same total script count. If you're evaluating an independent, ask specifically for revenue breakdown by generic, brand, and specialty.

**Immunization revenue:** Post-COVID, pharmacies that invested in immunization capacity (flu, COVID, shingles, travel vaccines) added a meaningful revenue stream that's relatively stable and recurring. Some independents generate $40K–$80K/year in immunization revenue. This is capitalized at standard dispensing multiples.

• Request revenue breakdown: dispensing (generic/brand/specialty) and front-end
• Identify specialty prescription volume and services offered
• Review immunization program revenue and trajectory
• Check compounding capabilities if any — can add 10–20% premium to valuation
• Understand front-end margin vs. dispensing margin — don't blend them in your EBITDA model

What Different Buyers Pay: Independent Buyers vs. Chain Acquirers

The buyer type determines the effective price ceiling for any pharmacy acquisition. Understanding who is bidding is as important as the underlying numbers.

**Chain acquirers buying independents:** CVS, Walgreens, and regional chains buy independents for DEA registration, script volume, and location access. They underwrite to their chain unit economics, not the independent's margin profile. They'll pay 4x–6x EBITDA for volume pharmacies (300+ scripts/day) but have little interest in sub-200-script-day operations.

Chain acquisitions typically move fast (45–60 days from LOI) and are all-cash or mostly cash. The downside: they rebrand immediately and the pharmacy's independent identity ends at close.

**Independent-to-independent sales:** The largest category by transaction count. Buyer is typically a pharmacist buying their first or second location. Price tolerance is 3x–5x EBITDA, SBA financed. Due diligence moves slower (60–90 days), timeline extends, but these buyers are often more flexible on deal structure (seller note, earnout, phased transition).

**Specialty buyer appetite:** Buyers focused on specialty pharmacy are willing to pay above-market multiples (5x–7x+ EBITDA) for pharmacies with established specialty relationships. If your target pharmacy has oncology or immunology volume, identify specialty-focused buyers as a parallel track.

For SBA financing options for pharmacy buyers, see SBA loans for pharmacy acquisitions. For acquisition mechanics from LOI through close, the pharmacy acquisition guide covers the full process.

Building Your Pharmacy Valuation Model: The Step-by-Step Approach

Here's a practical approach to building a defensible pharmacy valuation for LOI pricing.

**Step 1 — Normalize EBITDA.** Take the seller's P&L for 3 years. Add back: owner compensation above $140K/year, personal health insurance ($12K–$18K/year typical), retirement contributions, personal vehicle, any one-time expenses clearly documented as non-recurring. Subtract any expenses the seller may have understated (if the business is understaffed, add a market-rate pharmacist salary for the hours the owner worked unpaid).

**Step 2 — Adjust for DIR.** If using pre-2024 financials, add back the net DIR clawback amount for each year. Use the DIR reconciliation documents from each PBM. If those don't exist, estimate using industry benchmarks (typically 1–3% of Medicare Part D dispensing revenue for pre-2024 periods).

**Step 3 — Apply the multiple.** Based on script count, PBM stability, 340B status, and buyer type, select your multiple range. Build the case for where in that range the pharmacy falls. Don't default to the midpoint — build a narrative for why this pharmacy is in the upper or lower portion of the range.

**Step 4 — Stress test.** Model two scenarios: 10% script loss post-transition (typical range), and a PBM preferred network exclusion (20–30% script loss). Confirm you can still service your debt at DSCR 1.25x under the stress case.

**Step 5 — Cross-check with revenue multiple.** Divide your EBITDA-based valuation by TTM revenue. If the resulting revenue multiple is above 1.4x, you're at the high end of the market — make sure you have a compelling narrative for why this pharmacy deserves a premium.